Urology Times

A recent study validated the PROSTOX ultra test as a biomarker for predicting late-grade genitourinary toxicity following radiation treatment for prostate cancer. The test is comprised primarily of microRNA single-nucleotide polymorphisms (mirSNPs). According to the authors, these findings support the potential of mirSNPs to predict toxicity in these patients. Learn more 🔗 : https://lnkd.in/eKeckziN Amar Kishan, David Geffen School of Medicine at UCLA | #pcsm

In an interview with Urology Times®, Phillip Kuo, MD, PhD, FACR, outlined findings from the study, “Quantitative 68Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following 177Lu-PSMA-617 (VISION trial)." Overall, data showed that baseline 68Ga-PSMA-11 PET/CT whole-body tumor SUVmean was predictive for 177Lu-PSMA-617 efficacy. Specifically, a higher whole-body tumor SUVmean was associated with improvements in radiographic progression-free survival and overall survival. According to Dr. Kuo, these findings are becoming increasingly important, especially in light of the recent label expansion for 177Lu-PSMA-617 that moved the therapy into the pre-chemotherapy setting. Dr. Kuo noted, "Knowing how patients are going to benefit is going to play an even more important role as we move this earlier in the disease state for metastatic castration-resistant prostate cancer." Sign up to learn more from Dr. Kuo here 🔗 : https://lnkd.in/g5pGPwzj City of Hope | #pcsm

While vaginal estrogen is the preferred treatment for addressing the long-term symptoms of genitourinary syndrome of menopause (#GSM), there are barriers and misconceptions that limit its use, according to Ekene Enemchukwu, MD, MPH, FACS, FPMRS. Dr. Enemchukwu explains that when patients seek treatment for GSM, they are often told to use an over-the-counter vaginal moisturizer or lubricants, which she says only provide short-term relief. “To find a therapy that's all encompassing, that manages all of this in a long-term fashion, low-dose vaginal estrogen is the preferred treatment,” she says. “It's safe and it's effective at reducing the genitourinary and sexual symptoms.” Watch the full interview 🔗 : https://lnkd.in/ed2FhNGz Stanford Urology | #WomensHealth

EXCLUSIVE 🌟 : Sign up 🔐 to access our complete guide to the key developments set to shape urology in Q2 of 2025! This report outlines upcoming FDA decisions and can't-miss conferences for urology professionals. Stay ahead of the curve 🔗 : https://lnkd.in/e-cCERNu

Sunday Spotlight 🌟 : In a recent interview with Urology Times®, Matthew Galsky, MD, of Icahn School of Medicine at Mount Sinai, offered his thoughts on the significance of findings from the phase 3 #NIAGARA trial and the recent approval of perioperative durvalumab with neoadjuvant chemotherapy. The regimen recently received FDA approval for adult patients with muscle-invasive bladder cancer (#MIBC). 🔗 For more: https://lnkd.in/eWkdCpGe

The Inflation Reduction Act of 2022 included a provision, which took effect in 2025, capping out-of-pocket Medicare Part D prescription costs at $2000. In a recent interview with Urology Times®, Benjamin Pockros, MD MBA discussesd the potential impact of this cap for patients with urologic conditions such as prostate cancer. Pockros also shared details on online tools that can be used to decrease out-of-pocket costs for patients. 🔗 Read the full interview here: https://lnkd.in/eGHA7Y-p University of Michigan Medical School | #Urology

Article of the Week: Data from a real-world study showed that the Calyxo, Inc. CVAC 2.0 ureteroscope (CVAC2) demonstrated a safe and effective approach to stone clearance. Overall, patients achieved an average volume reduction of 94.2% ± 11 following CVAC2 (P = .008). The majority of patients (n = 5) achieved greater than 99% stone clearance. 🔗: https://lnkd.in/gDTu5UgT

The combination of lenvatinib and pembrolizumab is FDA-approved for patients with advanced renal cell carcinoma (#RCC). In a recent study, investigators sought to assess its efficacy and safety in patients with locally advanced, non-metastatic clear cell RCC. Overall, the combination showed promising clinical activity and an acceptable safety profile in this patient population. According to lead author Mehmet A. Bilen, MD, of Winship Cancer Institute of Emory University, these findings warrant further investigation. 🔗 Read the full interview here: https://lnkd.in/eBtiTkYB

The CD46-targeting antibody-drug conjugate FG-3246 demonstrated encouraging clinical activity and a manageable safety profile in patients with metastatic castration-resistant prostate cancer (#mCRPC). Data from the phase 1 study were published in the Journal of Clinical Oncology, showing a confirmed objective response rate of 20% and a median radiographic progression-free survival of 8.7 months. According to lead author Rahul Aggarwal, MD, of the University of California, San Francisco - School of Medicine, FG-3246 represents a promising new approach in mCRPC. 🔗 For more: https://lnkd.in/e5gXFKQj FibroGen, Inc. | #pcsm

The FDA has granted 510(k) clearance to Bright Uro's Glean Urodynamics System for patients with lower urinary tract dysfunction. The device enables wireless, catheter-free ambulatory urodynamics monitoring that can aid in decision-making for these patients. According to Bilal Chughtai, MD, this design may lead to more accurate test results. 🔗 For more: https://lnkd.in/eeaBw6hr